Use Of Cox-2 Inhibitor To Prevent T-cell Anergy Induced By Dendritic Cell Therapy

Abstract

The present invention relates to a method and combination therapy useful in the treatment of cancer. More specifically, the invention relates to the use of COX-2 inhibitors in combination with a therapeutic dendritic cell vaccine for treating cancer. The COX-2 inhibitors of the present invention are believed to inhibit the enzymatic activity of prostaglandinE2 (PGE2); thereby preventing COX-2 overexpressing tumors from evading immune surveillance by antigen-specific cytotoxic T lymphocytes (CTLs). COX-2 inhibitors are believed to suppress PGE2 that COX-2 overexpressing glioma produce, allowing tumor-infiltrating DCs to polarize Th cells toward Th-subset-1 (Th1).


Claims
Download PDF
Document Preview
Document History
  • Publication: Apr 28, 2005
  • Application: Oct 5, 2004
    WO US 2004/0032669 W
  • Priority: Oct 6, 2003
    US US 50894503 P

Download Citation


Sign in to the Lens

Feedback